AGEN - アジェナス (Agenus Inc.) アジェナス

 AGENのチャート


 AGENの企業情報

symbol AGEN
会社名 Agenus Inc (アジェナス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アジェナス(Agenus Inc.)は免疫腫瘍学(I-O)会社である。同社は癌と戦うために身体の免疫システムに関わる治療法の発見と開発に従事する。同社は、ヒト抗体を産生するように設計されたレトロサイトディスプレイ、SECANT酵母ディスプレイおよびファージディスプレイ技術を含む抗体発見プラットフォーム、チェックポイントモジュレーター(CPM)プログラムを含む抗体候補プログラム、並びにProphage、AutoSynVax、PhosPhoSynVax及びQS-21スチムロンアジュバント(QS-21スチムロン)を主とするサポニンベースのワクチンアジュバントを含むワクチンプログラムなどのプラットフォームとプログラムによって駆動されるI-Oポートフォリオを開発している。同社の発見パイプラインには、一連のチェックポイント変調(CPM)抗体が含まれる。ワクチンプラットフォームには、その熱ショックタンパク質(HSP)ベースのプロファージワクチン候補、およびその合成ワクチン候補のASVとPSVが含まれる。   アジェナスは米国のバイオ医薬品メ―カ―。主に、がん治療を目的に、免疫システム機能を調節するチェックポイント調節因子を標的とした抗体医薬品の発見、開発、商用化に従事。脳腫瘍、腎臓がん、肺がん、アルツハイマ―などの免疫治療用ワクチンの研究を行う。本社はマサチュ―セッツ州。   
本社所在地 3 Forbes Road Lexington MA 02421 USA
代表者氏名 Garo H. Armen ガロ・アーメン
代表者役職名 Chairman of the Board Chief Executive Officer Founder
電話番号 +1 781-674-4410
設立年月日 1994年
市場名 NASDAQ Small Cap
ipoyear 2000年
従業員数 255人
url www.agenusbio.com
nasdaq_url https://www.nasdaq.com/symbol/agen
adr_tso
EBITDA EBITDA(百万ドル) -113.91800
終値(lastsale) 2.07
時価総額(marketcap) 234493980.12
時価総額 時価総額(百万ドル) 223.16580
売上高 売上高(百万ドル) 29.24434
企業価値(EV) 企業価値(EV)(百万ドル) 193.05562
当期純利益 当期純利益(百万ドル) -150.89400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Agenus Inc revenues decreased 44% to $17.5M. Net loss applicable to common stockholders increased 61% to $78.9M. Revenues reflect Revenue (research and development) decrease of 61% to $12.1M. Higher net loss reflects Non-operating income (expense) decrease from $2.4M (income) to $1.4M (expense) GENERAL AND ADMINISTRATIVE increase of 23% to $16.3M (expense).

 AGENのテクニカル分析


 AGENのニュース

   Andy Hurley Named Agenus Chief Commercial Officer  2021/02/09 22:06:34 ADVFN UK
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline…
   Agenus Announces Agenus Insights - Virtual R&D Miniseries  2021/02/09 16:00:00 ADVFN UK
Season 1 Episode 1 (S1E1) on “Optimally Targeting TIGIT” LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ:…
   Thinking about buying stock in Canopy Growth Corp, 3D Systems, Bilibili, Agenus, or Vyne Therapeutics?  2021/02/04 14:31:00 PR Newswire
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, DDD, BILI, AGEN, and VYNE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Current Report Filing (8-k)  2021/01/14 21:02:29 ADVFN UK
AGENUS INC NASDAQ false 0001098972 0001098972 2021-01-12 2021-01-12 UNITED STATES SECURITIES…
   Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data - Stocks News Feed  2020/11/13 19:43:00 Stocks News Feed
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and… Read More »Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
   Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data - Stocks News Feed  2020/11/13 19:43:00 Stocks News Feed
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and… Read More »Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
   Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data  2020/11/13 19:42:58 ADVFN UK
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline…
   Agenus and Dr. Steven O’Day to Participate in Panels at the Virtual SITC 2020 Immuno-Oncology Event Hosted by B. Riley  2020/11/12 14:00:00 ADVFN UK
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline…
   First patient dosed in COVID-19 trial with allogeneic cell therapy  2020/11/09 09:51:02 European Pharmaceutical Review
The first patient with COVID-19 has been administered agenT-797, an allogeneic cell therapy made by Agenus Inc.
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data - Stocks News Feed  2020/11/13 19:43:00 Stocks News Feed
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven O’Day, Executive Director of the John Wayne Cancer Institute, Dr. Jennifer Buell, President and… Read More »Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
   Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data  2020/11/13 19:42:58 ADVFN UK
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline…
   Agenus and Dr. Steven O’Day to Participate in Panels at the Virtual SITC 2020 Immuno-Oncology Event Hosted by B. Riley  2020/11/12 14:00:00 ADVFN UK
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline…
   First patient dosed in COVID-19 trial with allogeneic cell therapy  2020/11/09 09:51:02 European Pharmaceutical Review
The first patient with COVID-19 has been administered agenT-797, an allogeneic cell therapy made by Agenus Inc.
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アジェナス AGEN Agenus Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)